Shopping Cart
- Remove All
Your shopping cart is currently empty
Belzutifan (MK-6482) is a potential treatment for clear cell renal cell carcinoma (ccRCC). Belzutifan is an orally active and selective HIF-2α inhibitor (IC50: 9 nM). Belzutifan , as a second-generation HIF-2α inhibitor, increases potency and improves pharmacokinetic profile.

| Pack Size | Price | Availability | Quantity |
|---|---|---|---|
| 1 mg | $64 | In Stock | |
| 5 mg | $155 | In Stock | |
| 10 mg | $228 | In Stock | |
| 25 mg | $433 | In Stock | |
| 50 mg | $695 | In Stock | |
| 100 mg | $987 | In Stock | |
| 200 mg | $1,330 | In Stock | |
| 1 mL x 10 mM (in DMSO) | $169 | In Stock |
| Description | Belzutifan (MK-6482) is a potential treatment for clear cell renal cell carcinoma (ccRCC). Belzutifan is an orally active and selective HIF-2α inhibitor (IC50: 9 nM). Belzutifan , as a second-generation HIF-2α inhibitor, increases potency and improves pharmacokinetic profile. |
| Targets&IC50 | HIF2α:9 nM |
| In vitro | PT2977 effectively and dose-dependently decreased mRNA levels of human cyclin D1, a target gene regulated by HIF-2α. It leads to a rapid and dose-dependent reduction in EPO expression[1]. |
| Synonyms | PT2977, MK-6482 |
| Molecular Weight | 383.34 |
| Formula | C17H12F3NO4S |
| Cas No. | 1672668-24-4 |
| Smiles | CS(=O)(=O)c1ccc(Oc2cc(F)cc(c2)C#N)c2[C@@H](F)[C@@H](F)[C@@H](O)c12 |
| Relative Density. | 1.56 g/cm3 (Predicted) |
| Color | White |
| Appearance | Solid |
| Storage | store under nitrogen,store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 50.5 mg/mL (131.74 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (5.22 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.